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The internationalization of innovation towards the South:  
A historical case study of a global pharmaceutical corporation in China 
(1993-2017) 
ABSTRACT 
Intensified competition means that multinational enterprises (MNEs) are increasingly concerned with 
locating innovation activities in the most appropriate locations. This had led to emerging economies in 
the South becoming an important destination of R&D-related foreign direct investment (FDI), 
departing from their traditional role as low-cost production sites. Thus far, however, our understanding 
of this transformation process is limited. The purpose of this article is therefore to explore the process 
by which foreign MNEs’ low-value-adding operations in the South are transformed into high-value-
adding R&D operations.  Drawing on the current literature, we construct a framework of evolution 
consisting of four major waves of R&D internationalization and corresponding R&D objectives. To 
better understand how these waves have evolved over time, we focus on the South and trace the 
process of change using a single historical case study: AstraZeneca in China between 1993 and 2017.  
We find evidence of idiosyncratic location-bound conditions offering both opportunities and resources. 
The gradual development of these favourable conditions, along with AstraZeneca’s deepening local 
knowledge, triggered a transformation process in their operations in China. Our study thus offers 
important historical insights, which present a platform for future research providing more nuanced 
theoretical explanations of the four waves of R&D internationalization.  
 
Keywords: R&D internationalization, emerging economies, North and South, historical case 
study. 
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Introduction  
The fast-changing global environment in recent years, including competition from 
multinational enterprises (MNEs) originating in emerging economies (which we term the ‘South’) and 
development of the Southern economies, has led to noticeable changes, both inside advanced-economy 
(which we term the ‘North’) MNEs and in host countries (Mudambi et al., 2014; Awate et al., 2015; 
D’Agostino, 2015; Jha et al., 2015; Nair et al., 2015; Zedtwitz et al., 2015). These include the 
increasing need to monitor and understand new global trends and hence to engage in multi-sourcing of 
knowledge inputs, a trend reinforced by rising R&D costs and a shortage of R&D personnel in the 
industrialized countries (Reddy, 1997; Chen, 2004). This has led to a strategic re-focusing of 
international innovation to simultaneously maximize the value of home-based knowledge and capture 
and synthesize local-based knowledge, both in the North (Zander, 1999; Chen, 2004) and in the South 
(Liu and Chen, 2012; Shin et al., 2016).  In addition, market and institutional conditions in the South 
have substantially improved (though at varying speed), including an increased supply of qualified 
R&D personnel and skills, government support, emergence of regional innovation systems, 
preferential policies, and an increasingly sophisticated consumer demand (Guan et al., 2009; Li, 2009; 
Liu et al., 2011). The combination of these factors, as well as wider developments in the advancement 
and availability of information technologies in knowledge management (Yu, 2011; Mabey and Zhao, 
2017), are driving the shift in innovation locus towards the South (Haour and Jolly, 2014; Haakonsson 
and Ujjual, 2015), with the aim of developing more sustainable competitive advantages by aligning 
internal and external knowledge networks globally. Consequently, in recent years MNE global 
innovation networks have extended to encompass the South (Liu and Chen, 2012; Jha et al., 2015; Jha 
et al., 2018) as is clearly evidenced by a recent study published by PriceWaterhouseCoopers (2015) 
that identified Asia as the top destination for corporate R&D expenditure, ahead of North America and 
Europe. 
Although this emerging trend is gaining a growing level of attention, research on R&D 
internationalization to date nevertheless takes a predominantly North-centric view. In comparison, 
studies addressing this trend using a South-centric lens remain sparse, with a few recent exceptions 
including Awate et al. (2015), Jain et al. (2015), Zedtwitz et al. (2015) and Mudambi and Santangelo 
3 
(2016). However, none of these studies were intended to provide the level of depth and detail that our 
article offers. Our historical case study approach is better able to capture the incremental changes in 
the South over a considerable length of time. It thus sheds new light on the historical development of 
four distinct waves of R&D internationalization derived from the current literature. As such, the 
objective of our study is not to test or re-examine the literature-informed waves. Instead it extends 
current literature on R&D internationalization towards the South by offering historical and contextual 
evidence of a micro-level study, i.e. AstraZeneca (AZ) in China, to be used for further theory 
development and empirical testing across other MNEs and/or Southern economies.    
We first construct an overarching framework of R&D internationalization, which encompasses 
innovation in both the North and the South. Extending existing literature, our framework integrates 
four major waves of R&D internationalization and their distinct R&D objectives through time. It 
moves from a North-North wave for home-based knowledge augmentation and a North-South wave 
for home-based knowledge exploitation, to a South-South wave for local-based knowledge exploration 
and a South-North for home-based knowledge augmentation. Building on this, we apply a historical 
(longitudinal) lens to the case of AZ in China to trace and analyze changes in its R&D activities from 
its first entry in 1993 to 2017. In so doing, our article answers the following two research questions:  
1) How have AZ’s operations in China evolved between 1993 and 2017 leading the country to play an 
increasingly active role in AZ’s R&D configuration?; 2) What can be learnt from the case of AZ in 
China in light of the existing literature and theories on R&D internationalization?   
Our article makes several key contributions. First, we construct a literature-informed 
comprehensive framework offering a classification of R&D internationalization waves and their 
corresponding R&D objectives. This framework explicitly illustrates and integrates four waves of 
R&D internationalization and their distinct R&D objectives in each wave, depicting the overall 
process of R&D evolution in the South. Second, in light of this framework we present a more 
complete picture of the R&D evolution process and the mechanisms underlying this process using the 
case of AZ China in the period between 1993 and 2017. Our comprehensive case study evidence offers 
new insights into how the South (in this case, AZ in China) has upgraded its role in R&D 
internationalization, thus focusing in particular on the last three waves of our framework of R&D 
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internationalization. It thus addresses the limitations of existing research, which lacks a solid micro-
level understanding of the incremental changes an MNE may experience inside a fast-changing 
Southern economy such as China. Third, by exploring the context of China, we offer new insights into 
the idiosyncratic institutional and market transformation of the country that impacted on AZ’s local 
R&D evolution. Whilst China is known to represent unique opportunities for MNEs, studies exploring 
its historical impact on MNE innovation activities remain sparse. Our article is one of the first to apply 
a longitudinal case study approach to reveal contextual details of R&D evolution in the South. Lastly, 
our article contributes to the methodological development in research on R&D internationalization 
research by way of applying a longitudinal historical approach to the study of R&D 
internationalization, a rather neglected approach (Welch and Piekkari, 2017). We demonstrate the 
suitability of a single case study in exemplifying ‘context’ in qualitative research (Siggelkow, 2007; 
Doz, 2011; Welch et al., 2011), when the phenomenon in question is relatively new or difficult to 
study. The empirical evidence of our study is not intended to generalize across the industry or across 
other Southern economies, but instead is to be used for further theory development to advance our 
understanding as to whether the case of AZ in China and the proposed pattern of R&D evolution 
towards the South are typical.  
In the remainder of this article, we first review the literature on R&D internationalization and 
construct an evolutionary framework. Then, we discuss our methodological approach and the 
background of our research context. This is followed by our case study findings. Finally, we discuss 
these findings and conclude with our contributions to theory development, implications for practice, 
and our recommendations for future research. 
The internationalization of R&D: Literature review and conceptual framework  
 
Literature review: R&D locations and objectives 
Dunning (1958), Safarian (1966) and Brash (1966) were amongst the first to discuss the act of 
internationalization of R&D displayed by some first-mover MNEs at the time. Soon after, an empirical 
study by Creamer (1976) provided clear evidence that a variety of overseas R&D activities were 
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performed by MNEs from the North. Cordel (1973) and Ronstadt (1978) offered typologies of 
different overseas R&D activities. Subsequently, Behrman and Fischer (1980), Hakanson (1981), 
Hood and Young (1982), Niosi (1999), and Edler (2007) recorded a shift of global innovation 
activities from MNE headquarters towards the active participation of foreign subsidiaries, which 
became more prominent as an important source of new knowledge generation (Feinberg and Gupta, 
2004; Griffith et al., 2004).  
Initially, these strategically important locations for new knowledge generation were typically 
either geographically close or institutionally similar countries, so that MNEs could retain close control 
over key activities whilst also benefiting from locational advantages (Song and Shin, 2008; Song et 
al., 2011). Hence, a large majority of MNEs chose to locate their international innovation activities in 
developed countries, particularly in the USA, Europe, and Japan, while also transferring innovations to 
and back from other developed countries (Niosi, 1999; Edler, 2007; Haour and Jolly, 2014; 
Haakonsson and Ujjual, 2015). Although these studies provided valuable theoretical and empirical 
insights at the time, they were predominately underpinned by North-centric developments and 
thinking, whilst the South remained an ‘outsider’ in the MNE global innovation network (Liu and 
Chen, 2012). Drawing on the terminology of ‘waves’ from the works of Coe et al. (1997) and Jha et 
al. (2015), we classify this trend as the North-North wave which is mostly reflecting ‘home-based 
knowledge augmentation’ (HBKA-N) within Northern economies.  
 A second stream of literature has noted innovation-related knowledge transfer from 
headquarters to less developed economies in the form of production offshoring paired with on-site 
technical support and backup required to ensure timely problem-solving (Florida, 1997). Furthermore, 
the global investment environment witnessed significant changes, such as increasing international 
competition and advancing information technology (Castellani and Zanfei 2006; Yu, 2011). We classify 
this development of limited R&D activities in the South as the North-South wave, which is closely 
aligned with Vernon’s (1966) product life cycle model whereby existing product knowledge is further 
exploited in new locations. Consequently, for the first time, the South became a destination for R&D 
activities, though this was generally viewed as more of an ‘operational necessity’, restricted to 
production (Cantwell, 1992; Pearce and Papanastassiou, 1997). Drawing on previous literature on the 
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objectives and characteristics of R&D internationalization (Kuemmerle, 1999; Bas and Sierra, 2002; 
von Zedtwitz and Gassmann, 2002; Liu and Chen, 2012), this wave can be identified to reflect the main 
objective of ‘home-based knowledge exploitation’ (HBKE-S) in supporting the development of new 
markets and foreign production sites. 
As home-based knowledge exploiters, MNEs chose to locate their R&D units close to large 
foreign markets or manufacturing sites to ensure on-time support. The main tasks of these R&D units 
tended to include assimilating knowledge transferred from the headquarters, modifying existing 
manufacturing processes, or modifying existing products to meet the local market conditions in the 
host countries (Pearce and Papanastassiou, 1999; Athreye et al, 2016). By doing so, MNEs could gain 
economic return from utilizing their existing proprietary knowledge (generated in the North) in 
overseas locations (such as the South), while home-based R&D units continued to define the product 
specifications and design the manufacturing processes (Schmiele and Mangelsdorf, 2009; Liu and 
Chen, 2012). 
 A third and fourth stream of literature has emerged in recent time which suggests the 
increasingly crucial role of emerging economies in undertaking innovative activities for MNEs by 
incorporating the development of global innovation networks that excel at tapping into new centres of 
knowledge (Dunning and Lundan, 2009; D’Agostino and Santangelo, 2012; UNCTAD, 2012; 
Castellani et al., 2013; Jain et al., 2015; Mabey and Zhao, 2017). What makes these two streams 
significant is that Southern economies are no longer viewed only as the location for low-cost labour or 
primary resources, but also potential sources of new knowledge (Prabhu and Jain, 2015). Some of the 
latest studies further support the growing proportion of FDI now devoted to strategic innovation in 
emerging economies, particularly Asia (Altenburg et al., 2008; Castellani et al, 2013; Athreye et al, 
2014; Prashantham and Dhanaraj, 2015; Bresciani et al., 2016). These innovation investments target 
both the local market (we term this the ‘South-South’ wave) and the global market (we term this the 
‘South-North’ wave). This significant development has been the focus of some of the latest research 
(e.g. Awate et al., 2015; Jha et al., 2015; Jha et al., 2018; Mabey and Zhao, 2017).  
In terms of the South-South wave, the main objective of the MNE concerns ‘local-based 
knowledge exploration’ (LBKE-S) in support of the development of new products for local and 
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regional markets (Jha et al., 2015). R&D units under the South-South wave are focused on the seeking 
and development of knowledge useful in providing products to local markets (Jha et al., 2015). In 
situations where market demand is high and the availability of products is low, an opportunity arises 
for local-based R&D units to fill this gap by developing market-specific products. This leads R&D 
units to seek localized knowledge from entities such as research institutions, universities, local firms, 
and customers (Awate et al., 2015), and combine this knowledge with its existing internal capabilities 
to realize new or improved products that are market-specific. In terms of the South-North wave, MNEs 
are mainly engaged in ‘home-based knowledge augmentation’ (HBKA-S) in support of the 
development of complementary and novel knowledge for the global market. R&D units under the 
South-North wave are concerned with the development of long-term innovative capabilities by taking 
advantage of novel or complementary knowledge in foreign locations, which is gaining growing 
importance and is driven by the pressure of knowledge-based competition (Jha et al., 2015; Jha et al., 
2018). To augment their home-based technologies, MNEs set up their R&D units overseas with an aim 
to access the host countries’ knowledge for their headquarters (Asakawa and Som, 2008). One main 
objective of these units is to engage in knowledge sourcing and to benefit from potential knowledge 
spillovers (Almeida and Kogut, 1999; Feinberg and Gupta, 2004).  
Nevertheless, both these waves reflect a picture that is dramatically different from the 
conventional view of R&D internationalization. MNEs no longer regard the South only as a target for 
market expansion and production, accompanied by limited R&D activities, but also as an important 
location for knowledge augmentation. Reverse knowledge transfer from the South to the North thus 
becomes a distinct possibility (Govindarajan and Ramamurti, 2011; Govindarajan and Trimble, 2012). 
This departs from the product life cycle understanding of knowledge exploitation and moves towards a 
global innovation network arrangement of differentiated and distinct R&D units worldwide (Mudambi 
and Santangelo 2016). These R&D units, located in the North and the South, span across a wide 
variety of R&D activities.  
 Drawing on the four streams of literature, Table 1 summarises our classifications of each of 
the four waves and associated R&D objectives. 
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Table 1. Classification of the four major waves in MNE R&D internationalization  
North: advanced economies (e.g. US, UK, Germany, Japan) 
South: emerging economies (e.g. China, India, Brazil) 
 
 Location  R&D objectives 
Wave 1  North-North Home-based knowledge augmentation in the North (HBKA-N) 
Wave 2  North-South Home-based knowledge exploitation in the South (HBKE-S) 
Wave 3  South-South Local-based knowledge exploration in the South (LBKE-S) 
Wave 4  South-North Home-based knowledge augmentation in the South (HBKA-S) 
 
2.2. An overarching conceptual framework: the internationalization of R&D towards the South 
Whilst the four waves of R&D internationalization have been identified in prior research, they 
have remained largely independent as most studies focused on issues within the respective waves. In 
conventional North-North and North-South innovation paradigms, R&D stayed largely in the North 
whilst MNE activities in the South were predominantly driven by knowledge exploitation to meet 
growing local market demand. This reflected a highly hierarchical relationship between the North and 
the South. However, in the latest development of MNE R&D internationalization, Southern economies 
such as China (Bruche, 2009; Liu and Chen, 2012) and India (Kumaraswamy et al., 2012; Awate et 
al., 2015; Jha et al., 2015) have emerged as high-profile destinations in attracting inward innovation 
FDI. Some of the latest evidence (e.g. Liu et al., 2011; Liu and Chen, 2012) suggests that MNE R&D 
mandates in these locations have increasingly gone beyond the traditional pattern of knowledge 
exploitation. Pearce (2004; 2006), Dunning and Lundan (2008), and Zhang et al. (2018) have found 
that technological dynamism tends to shape the internal organisational structure of the MNE, which 
often explains the initial and subsequent strategic motivations of overseas subsidiaries. The strategic 
motivation underlying the establishment of subsidiaries in different countries depends on the 
locational opportunities and advantages that are present at the time of the initial investment. For 
instance, initially, market- and efficiency-seeking subsidiaries were mostly established in the South 
whilst knowledge-seeking subsidiaries were established in the North. Market- and efficiency-seeking 
motivations, which are underpinned by the strategic rationale of asset exploitation (Bartlett and 
Beamish, 2013; Dunning and Lundan, 2008), are intended to benefit from local resource abundance by 
investing in a particular country or region to supply goods or services to local, regional, and/or global 
markets. A knowledge-seeking motivation, on the other hand, concerns “the pursuit by MNEs of new 
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technological capabilities, scientific capacity (research facilities) and creative expertise (e.g. 
dimensions of tacit knowledge) from particular host countries, in order to extend the overall 
competences (product range and core technology) of the group” (Manea and Pearce, 2004:4). As the 
local environmental conditions in the South continue to evolve, benefits of an embedded innovation 
capacity for developing goods in and for host markets and regions become apparent. As a result, initial 
motivations of market- or efficiency-seeking can often shift towards local innovation through ‘asset 
augmenting’ activities (such as knowledge-seeking) (Bartlett and Beamish, 2013; Cantwell et al., 
2010; Dunning and Lundan, 2008; Zhang et al., 2018). 
Recent work by von Zedtwitz et al. (2015) extends the concept of ‘reverse innovation’ by 
asserting that emerging economies are not simply locations for innovation adoption but also for new 
knowledge development. This implies that apart from knowledge exploitation (wave 2), local-based 
knowledge exploration (wave 3) and home-based knowledge augmentation (wave 4) are seen to take 
place in the South as R&D units become deeply involved in the local context with increased benefits 
of access to external knowledge, hiring of local personnel, and support of the local government.  
Drawing on previous literature (Cantwell and Iammarino, 1998; Cantwell and Janne, 1999), 
one explanation for this development could be that countries with abundant innovation resources and a 
favourable supporting environment can influence the mandate of local R&D units (Ito and Wakasugi, 
2007; Liu and Chen, 2012). In the case of certain economies in the South such as India and China, this 
is increasingly evident (Lu et al., 2008; Dodgson, 2009; Castellani et al., 2013). For instance, 
institutional conditions for innovation in these countries are fast improving through the efforts of 
national and local governments. Several pro-innovation factors can be identified: investment in higher 
education and the retention of skilled native and foreign researchers and managers (Yang and Jiang, 
2007), development of clusters (encompassing local firms and support systems), and the establishment 
of national systems of innovation (encompassing MNEs, indigenous firms, public and private research 
institutions, universities, involving in a variety of innovation activities) (Archibugi and Iammarino, 
2002; Lundvall 1992; 2007; Dodgson, 2009).  As a result, these economies benefit from an 
accumulation of innovative capabilities (Lema et al., 2015).  As part of these changes, subsidiaries in 
these locations are offered the opportunity to improve their innovation capabilities
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study by Zhang and Pearce (2012) finds that subsidiaries in China are not solely receivers of MNE 
knowledge, but also generators of new knowledge by working closely with local universities, firms, 
and research institutions. In particular, they argue that while market-seeking subsidiaries are 
frequently found in emerging economies, some of these economies have developed impressive 
innovation capacity for generating new knowledge, contributing de novo to the MNE’s technological 
trajectory. Thus, new knowledge generated in the South not only better captures the Southern market 
but can also be valuable to MNE global competitiveness (Mudambi and Santangelo, 2016). The 
locational hierarchy between the North and the South is thus flattening, whereby the South is starting 
to become part of MNEs’ global innovation network for knowledge augmentation (Chen, 2004; Liu 
and Chen, 2012). Nevertheless, this changing relationship between the North and the South, and the 
shift towards R&D in the South, does not happen instantly; instead, MNE R&D internationalization 
from the North to the South is likely to go through an evolutionary process. However, to date, studies 
attempting to directly map this pattern across the waves remain scarce (Govindarajan and Ramamurti, 
2011; von Zedtwitz et al. 2015).  
 In this study, we assert that the waves in R&D internationalization are not static or unrelated. 
Instead, they are parts of a dynamic development in which the growth of innovation within MNEs has 
shifted towards the South. In Figure 1 we illustrate the gradual shift in MNE R&D internationalization 
from the North to the South. During the first wave (North to North), the global innovation network 
only spanned across advanced economies, termed the first-tier location with the accompanying R&D 
objective being mainly HBKA-N. Thereafter, the South was considered a second-tier location 
predominantly for the purpose of HBKE-S to meet growing market demand. Subsequently, the 
increased efforts in improving innovation capability and the fast-growing national economies in the 
South made them an increasingly attractive hub for LBKE-S, thus adding a third-tier location to the 
global innovation network. In the most recent wave, further strengthening of innovation capabilities in 
the South has led to HBKA-S and thus a fourth tier emerged. In short, the framework proposes that the 
four waves found in literature can be considered as four consecutive processes of R&D 
internationalization whilst they are also mutually inclusive to represent a multi-layered continuous 
network of global innovation.  
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Figure 1. Four-wave framework of MNE R&D internationalization 
 
 
Therefore, this article proposes that MNE R&D internationalization towards the South is 
likely to show a dynamic pattern, from HBKA-N and HBKE-S to LBKE-S and HBKA-S. Hence, our 
empirical study takes MNE subsidiaries in the South as the appropriate unit of analysis in light of this 
latest development in R&D internationalization (Liu and Chen, 2007; 2012). Furthermore, to address 
the empirical problem noted by Liu and Chen (2012): “the spatial distribution of innovation resources 
and potential is not even… [in the case of emerging economies]” (p:1109), we take a country-specific 
approach to better deal with such an unevenness and account for host-country idiosyncrasies. 
Moreover, since MNEs’ decisions to undertake R&D in specific locations are conditioned by both firm 
and location related factors, a context-specific view of the pattern of MNEs’ evolution in their local 
activities is essential. As each MNE is a nexus of knowledge flows across home and host countries 
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(Gupta and Govindarajan, 1991), how they pursue certain knowledge objectives by organizing specific 
R&D activities with local firms, research institutes, and universities in a host country becomes an 
important question. Nevertheless, studies adopting an evolutionary perspective to explore the pattern 
of R&D internationalization in the South remain limited. Jha et al. (2015), Jha et al. (2018) and 
Kumaraswamy et al. (2012) are rare exceptions; however, all focus on India and cover a maximum 
period of ten years.  
In sum, drawing on the literature on R&D internationalization, this article attempts to address 
the key question of how MNE R&D activities in the South have evolved to play an increasingly active 
role within the MNE global innovation network, so that new insights into the latest shift in R&D 
internationalization from the North to the South can be gained. Here, we take a historical lens to 
identify empirically the potential pattern of change in subsidiaries’ innovation activities of a specific 
MNE, AZ, in the case of a specific Southern economy, China. The next two sections first discuss the 
specifics of the case study approach (AZ in China), and then provide our empirical findings covering 
the period between 1993 and 2017. 
 
Epistemology and methodology  
To achieve a holistic understanding of the overall development pattern of R&D 
internationalization in our case study, we decided to adopt a longitudinal historical perspective, which 
echoes a similar approach taken by Jha et al. (2015) and Kumaraswamy et al. (2012). We follow 
Turnheim and Geels’ (2013) process-tracing approach to explore the evolution of AZ in China from its 
initial entry in 1993 to 2017. This approach is particularly useful in capturing the evolutionary pattern 
we seek to unfold in this study as it “takes path dependence seriously and goes ‘inside the black box’ 
to explain how actions and changing contexts produce event chains” (Turnheim and Geels, 
2013:1754). We adopt an epistemological style commonly used by historians, ‘narrative explanation’, 
which is particularly strong in capturing complex social interactions through time and event sequences 
(Abbott, 2001; Gill et al., 2018). 
 In line with Turnheim and Geels (2013), the narrative explanation style that we adopt in this 
article is not about simply describing separate events, but involves the tracing of the historical process, 
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guided by prior literature and the proposed conceptual framework (Figure 1). On the other hand, 
“historians rarely perform formal tests of theories; instead, they judge theories and conceptual 
frameworks for their usefulness in writing plausible and interesting narratives” (Turnheim and Geels, 
2013:1755). Therefore, using a ‘thick’ descriptive case study (Child et al., 2012) allows us to derive 
insights related to existing knowledge (Doz, 2001:584). Welch et al. (2011) proposed that 
contextualization should not be viewed as a limitation of case study research, but, on the contrary, as a 
bridge to ‘reconcile’ the positivist views on the generalizability of findings, which is regarded as 
fundamentally opposed to ‘explaining’ and ‘contextualizing’ (p:743). Applying this to our study, we 
argue that the contextual details of our case are simply too important to ignore. Thus, in order to fully 
understand the evolutionary pattern of R&D activities of AZ in China, it is important to complement a 
‘positivist context-free orientation’ with a more contextualized explanation, highlighting causal 
relationships. The objective of our study is thus to provide an analytical narrative that traces the 
pattern of R&D internationalization identified in the literature, but then emphasizes the impact of 
context, thus becoming an ‘explanatory’ tool of understanding, hence departing from its initial 
‘exploratory role’ (Yin, 2014). 
Within case study research, researchers can choose to select either single or multiple cases. 
The decision on which to use is largely dependent on its appropriateness in dealing with the topic 
(Yin, 2014; Fletcher et al., 2018). As the topic of this study is about drawing on rich contextual details 
to unfold an evolution pattern, a single case study of AZ in China is chosen. Siggelkow (2007) 
emphasizes the usefulness of a single case study as an important source for both unique data evidence 
and theorising. Our chosen case is empirically appropriate for several reasons. First, UNCTAD’s 
(2005) ranking of innovation-related FDI shows that China has become a top inward innovation FDI 
destination of the South. This is confirmed by a recent report by PriceWaterhouseCoopers (2015) that 
also identifies China as a recipient of some of the largest global R&D investments. Second, amongst 
many R&D intensive MNEs, AZ PLC has one of the oldest operating histories in China and was one 
of the very first to set up a strategic R&D centre in the country (Bernstein Research, 2009), thus 
providing the longest and richest story.  
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Case study rigor 
 In this article, we present a rigorous single case study, relying on the strategies, principles and 
coding rules described in Cook and Campbell (1979) and Gibbert and Ruigrok (2010). Thus, in Table 
2 we present the four validity and reliability criteria, namely internal validity, construct validity, 
external validity and reliability. These criteria are considered as the ‘primary reports’ along the 
horizontal axis. We also discuss the research measures taken in our study for each corresponding 
criterion, the ‘secondary reports’ along the vertical axis, drawing on Yin (2014). 
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   Table 2. Prim
ary and secondary reports considered 
 
 
Prim
ary R
eports 
(C
ook and C
am
pbell 1979; G
ibbert and R
uigrok 2010) 
 
Secondary Reports 
(Yin 2014) 
Internal validity 
C
onstruct validity 
External validity 
R
eliability 
 R
equirem
ent and actions taken: 
 
✓
 
Literature-inform
ed research 
fram
ew
ork (refer to ‘literature 
review
’ section) 
 
✓
 
Pattern m
atching w
ith other 
w
orks (refer to ‘discussion’ 
section) 
 
✓
 
Theoretical triangulation for 
the conceptualization and 
interpretation of findings 
(refer to ‘literature review
’ 
and ‘discussion’ sections) 
 R
equirem
ent and actions taken: 
 
✓
 
D
ata triangulation (refer 
to Table 3), cross checks 
of corporate reports and 
reports from
 the M
inistry 
of C
om
m
erce, P.R
.C
., 
w
ere m
ade to ensure all 
key activities of A
Z w
ere 
captured; confirm
ation 
from
 tw
o A
Z senior 
scientists 
 
✓
 
R
eview
 of drafts by 
m
ultiple non-authoring 
academ
ics 
  
 R
equirem
ent and actions taken: 
 
✓
 
R
ationale for case selection; 
evidence of A
Z as an 
appropriate case; em
bedding 
the case in the context of 
C
hina; industry inform
ation 
(refer to ‘m
ethodology’ and 
‘A
Z
 in C
hina 1993–2017’ 
sections) 
 
✓
 
D
etails on case study 
context (refer to ‘A
Z
 in 
C
hina 1993-2017’ section) 
 
 R
equirem
ent and actions taken: 
 
✓
 
C
ase study database 
(refer to Table 3) 
 
✓
 
N
am
e given for the 
organization in question 
(A
Z PLC
) 
 
✓
 
C
ase study protocol 
(refer to the subsection 
‘data analysis protocol’) 
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With reference to Turnheim and Geels’ (2012; 2013) definition of secondary (journal 
articles and authored books) and primary (newspapers, government reports and company annual 
reports) data, we draw on a wide variety of secondary and primary sources to highlight and trace 
activities of AZ during its operations in China. Although these sources cannot always be taken at 
face value, they do provide some interesting facts for our qualitative analysis, which tracks the 
gradual changes in the company’s operations and it can be said that “This variety in data sources 
enables triangulation, and allows for a rich analysis…” (Turnheim and Geels, 2013:1755). A 
comprehensive list of data sources is provided in Table 3. 
Table 3. Primary and secondary data sources 
Data (in alphabetical order) Source 
  
Books ▪ China Medical and Pharmaceutical Industry Handbook 
▪ The Asia-Pacific Biotech Directory 
▪ International Directory of Company Histories 
▪ Foreign Companies in China Yearbook 
  
Company Annual Reports ▪ AZ PLC 
▪ Zeneca Group PLC 
  
Corporate News Releases ▪ AZ Global 
▪ AZ China  
▪ Ironwood Pharmaceuticals Inc. 
  
Government Reports ▪ China Food and Drug Administration 
▪ Ministry of Commerce, P.R.C. 
▪ State Intellectual Property Office (China) 
  
Industry Reports ▪ Bernstein Research 
▪ Bio Partnerships Asia 
▪ Chemical Market Reporter 
▪ KPMG Research 
▪ McKinsey Quarterly 
▪ Thomson Reuters  
  
Newspapers ▪ Asia Pacific Biotech News 
▪ CBS News 
▪ China Daily 
▪ Jiangsu News 
▪ The Financial Times 
▪ The Independent 
▪ The Telegraph  
▪ Wall Street Journal 
▪ Washington Business Journal 
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Data analysis protocol 
The data analysis process was partially planned and partially emergent as the data 
collection progressed. Appropriate adjustments were made throughout the study by examining 
emerging patterns from the raw data, thus making the process interactive. Following a similar 
approach in Kumaraswamy et al. (2012), our longitudinal case is divided into three distinctive 
periods (covering waves 2 to 4 of our framework), using the narrative to depict AZ’s innovation 
activities in China. Specifically, period one displays an initial focus on market expansion and 
production in China together with the necessary low-level R&D activities for local adaptation (i.e. 
a North-South wave), while period two features a new focus on local and regional innovation and 
production, and period three is characterised by a shifting focus towards global-driven innovation. 
We then provide interpretations of those R&D activities undertaken in each period, as well as over 
the course of the three periods mentioned above in relation to our proposed overarching 
framework.  
Case company: Brief history of AZ PLC 
The beginning of AZ can be traced back to 1913 when Astra was an independent company 
based in Sodertalje, Sweden. It was not until the 1930s, however, that the company started its first 
small-scale research activities. The company acquired a couple of factories in 1939 and 1942, 
helping to make Astra the largest Swedish pharmaceutical company. From the early 1990s, Astra 
started to experience significantly increasing costs for the development of new drugs. Believing 
that the company needed a more international platform for the future, Astra started to look for 
partners. It was not long before Zeneca stood out as the ideal partner (The Independent, 1998). This 
partnering was one of the largest-ever European mergers at the time and made the combined 
company into the fourth largest pharmaceutical company in the world. The merger also signalled 
the company’s intention to strengthen its innovation and world market share in the long run. 
 The integration of the two companies’ worldwide organizational activities post-merger 
called for some major structural changes and, consequently, led to the formation of a new group 
arrangement, whereby a much-widened geographical scale was realized. Specifically, while a new 
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focus was starting to be placed on the Asia Pacific, Latin America and the Middle-East as younger 
markets with greater growth potential in the long term, the USA, Canada and Europe remained the 
three largest and most mature markets for the group. Hence, across these six markets, the overall 
emphasis was still placed on the North and three worldwide strategic innovation centres in Sweden, 
the UK and the USA were responsible for the most advanced drug research for the Northern 
market. This period of operation can be characterized as a part of the North-North wave, with the 
main objective of HBKA-N. The next section focuses on exploring R&D activities of AZ in China 
in the context of the North-South, South-South, and South-North waves, and HBKE-S, LBKE-S, 
and HBKA-S objectives respectively.  
Empirical findings: AstraZeneca’s R&D internationalization in China, from 1993 to 
2017 
Three distinctive periods in AZ’s internationalization of R&D activities in China can be 
identified. Below, we discuss each of these periods and the corresponding waves and innovation 
activities in more details. 
Initial expansion in China (1993–2001): The North-South wave and HBKE-S  
Since the announcement of ‘open door’ policy in 1978, China has carried out major 
economic reforms to move towards a more market-based system of trade and economic growth 
and to open up for foreign investments in low value-adding and factor-endorsed areas – a 
reflection of the abundance of low-cost labour and the absence of national innovation capabilities. 
This shift drastically accelerated China’s economic expansion and was the deciding point for Astra 
to establish its first sales and marketing subsidiary in the country: Astra (Wuxi) Pharmaceuticals 
Co. Ltd, in Jiangsu Province, not far from Shanghai (Pederson, 2008; World Scientific, 2003).  
Jiangsu was an ideal location for Astra for a number of reasons. First, in 1992, many parts 
of Jiangsu Province were turned into economic zones and Wuxi city established Wuxi New 
District – one of the largest industrial parks in China. The new district was known for providing 
strong support for international operations. Second, Jiangsu Province is ideally located next to 
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trade intensive regions, such as Zhejiang, and is home to hundreds of thousands of businesses. 
Third, the local government offered many incentives to attract FDI. Hence, the overall business 
environment of Wuxi made it the ideal location in China at the time of Astra’s entry. 
In the following year, Zeneca also entered China through a joint venture with Sinopharm, 
a state-owned corporation. Sinopharm, also known as China National Pharmaceutical Group 
Corporation, was the largest pharmaceutical and healthcare group in China at the time and already 
had a well-established network in the country. The initial agreement between Sinopharm and 
Zeneca was for the sole distribution of Zeneca’s leading drugs at the time (Zeneca Group PLC 
Annual Report, 1994; Heathcote, 1994). Similar to Astra, this move was also an indication of 
Zeneca’s attempt to enter into the Chinese market early as part of their global expansion strategy 
for existing products. One year into the agreement, Zeneca realized the huge potential of the 
Chinese market and established its own sales and marketing operations in 1995. Benefiting from 
the rapid economic growth in China in the following years, Astra and Zeneca both successfully 
positioned themselves in the Chinese market to be leaders in the sale of specific drugs. They also 
set up offices in over 20 major cities. However, Zeneca’s Chinese joint venture demerged around 
the same time as Astra and Zeneca merged. 
Following the merger between Astra and Zeneca, the new AZ embarked on its most 
significant Chinese venture at the time, i.e. an accumulative investment of US$270 million (in 
comparison to a US$121 million investment by GlaxoSmithKline around the same time) in 
building its first world-class production facility in Wuxi New District, where Astra’s previous 
Chinese operations had been initiated (Chemical Market Reporter, 2001). The new production 
plant employed 600 workers and produced 95% of all AZ’s products sold in the China. It is worth 
noting that whilst there are other pharmaceutical MNEs with local production facilities in China, 
AZ was seen to have the largest facility in terms of the scale of investment and the facilities 
created (Wall Street Journal, 2001; AstraZeneca Annual Report, 2001). This reflects a strong 
strategic emphasis on HBKE-S in the country and first sign of the North-South wave.  
During this period, AZ also made its first investment in R&D in the country – another step 
under the North-South wave. Between 1996 and 2001, AZ undertook nine international 
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multicentre clinical trials in the respiratory field in China, with the involvement of over 130 
domestic hospitals and institutions. By 2001, AZ had invested US$35 million in clinical trials and 
conducted 37 clinical research projects involving approximately 20,000 patients at more than 
1,000 domestic medical sites. The objectives of these investments were to develop drugs that were 
effective for Chinese patients with specific diseases.  To further its efforts in local innovation, AZ 
emphasized the importance of strategic partnerships with Chinese research institutions. For 
instance, AZ and Shanghai Jiaotong University launched a joint research project to investigate the 
genetic links to neuropsychiatric diseases (AstraZeneca Annual Report, 2001; China Daily, 2001).  
Although the research-related activities during this period were not intended to include 
building its own innovation facilities, AZ was still one of the first foreign companies to commit to 
market expansion in the form of HBKE-S at the time. This move benefited the company for two 
reasons. First, China was considered a marketplace where mature drugs could still generate sales 
long after patent expiration. Second, the common practice in China for drug selection was that 
once particular branded drugs were accepted by the doctors and patients, there was a strong 
tendency to stick to them permanently (AstraZeneca Annual Report, 2010; China Food and Drug 
Administration, n.d.). Hence, the development pattern of this period signals a heavy overall 
strategic emphasis on market expansion through HBKE-S rather than any other R&D activities, 
possibly due to the weak institutional conditions at the time, such as the lack of availability of 
R&D resources and government support policies. 
Second period of expansion in China (2002–2008): The South-South wave and LBKE-S 
Since 2002, there were two major developments in China. One was the continuation of a 
series of innovation programmes by the government, including the International S&T Cooperation 
Program of China; National Key Technologies R&D Program; and the Torch Program for 
supporting commercialization of high tech products (China Ministry of Science and Technology, 
n.d.). The other was the fact that the country officially became a member of the World Trade 
Organization (WTO). This had two major effects – encouragement for increased inward FDI and 
greater transparency in legal protection for foreign investors. Consequently, AZ deepened its 
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innovation involvement in China (Ministry of Commerce, P.R.C., 2005; AstraZeneca Annual 
Report, 2008). Despite China being viewed by most foreign investors as a more attractive 
destination for production and sales rather than research, extensive local partnering (Table 4) and 
the establishment of its own Chinese-based research institutions demonstrated AZ’s shift of focus 
in its operation in China from HBKE-S towards LBKE-S, which is indicative of the South-South 
wave.  
 
Table 4. List of local partnerships 
Year of 
Formation 
Chinese 
Partners  
R&D 
Activities 
2003 Peking University’s Guanghua 
School of Management 
To fund the China Centre for 
Pharmacoeconomics and Outcomes Research 
 
2007 
 
Peking University Third 
Hospital 
 
To set up the company’s first Clinical 
Pharmacology Unit in the country 
 
2007 
 
Guangdong Provincial People’s 
Hospital 
 
To augment existing clinical research 
capabilities and to undertake Phase I clinical 
research 
 
2008 
 
Shanghai Institute of Materia 
Medica 
 
To establish the Drug Safety Evaluation Joint 
Research Centre for speedy entry into the 
market 
 
2008 
 
Pharmatech Wuxi 
 
To synthesize compounds to increase the overall 
collection of compounds 
 
Specifically, AZ took a major step in 2003 by forming its most significant partnership at 
the time with Peking University’s Guanghua School of Management to fund the China Centre for 
Pharmacoeconomics and Outcomes Research. This was the first in a series of research and 
educational programs aimed at supporting reform of China’s healthcare system. During the first 
three years of the partnership, AZ provided over US$360,000 in sponsorship to help set up and 
establish research, advisory and training programs for government officials, hospital executives 
and pharmacy directors. 
AZ took another major step in its local development by forming a strategic partnership 
with Peking University Third Affiliated Hospital in 2007 to set up the company’s first Clinical 
Pharmacology Unit in the country (China Daily, 2007). In the same month, AZ and Guangdong 
Provincial People’s Hospital jointly established a research laboratory with a focus on translational 
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science. The unit was intended to augment existing clinical research capabilities and undertake 
Phase I clinical research, including clinical pharmacology and safety evaluations – steps necessary 
for launching new medicines in China. This move accelerated the launch and patient access to new 
medicines in China. In 2008, AZ reached out to the Shanghai Institute of Materia Medica to 
establish the Drug Safety Evaluation Joint Research Centre in Shanghai Pudong Science Park of 
the Chinese Academy of Science. This was also intended to accelerate the speed to market for 
drugs in the country. In the same year, the agreement between AZ and Pharmatech Wuxi came to a 
successful end, achieving its intended targets two months ahead of schedule, but AZ decided to 
extend its contract with the company to continue to synthesize compounds according to AZ’s 
designs to further expand the company’s global compound collection. 
In terms of establishing its own research institutions, AZ set a number of historical 
records. For example, AZ was the first company of its kind to launch a localized Clinical Research 
Unit for the East Asian region in Shanghai in 2002. The significant number of high quality medical 
talent available in the city was the reason for the location decision. The unit’s aim was to oversee 
East Asian clinical research in mainland China, Hong Kong, Taiwan and Korea, with the clinical 
research conducted by more than 40 high-calibre Chinese researchers. This signalled that the 
country would become a critical component of AZ’s future global trials and it had the potential to 
significantly reduce the time it took for drugs to be made available to Chinese patients 
(AstraZeneca Annual Report, 2002; Ministry of Commerce, P.R.C., 2005). 
Another important development came in 2006 when AZ invested more than US$70 
million in the establishment of the Innovation Centre China, which again was the first of its kind in 
the country (Ministry of Commerce, P.R.C., 2006; AstraZeneca Annual Report, 2006; China 
Pharmaceutical Industry Investment Promotion Report, 2014). It was also one of the most 
advanced scientific research centres of the Group outside of the UK, Sweden or the USA and 
provided firm evidence of the company’s dedication to research in China, as well as its ambition to 
have a strong innovation presence in the region. Although the beginning of AZ China did not seem 
to suggest so, the formation of this innovation centre illustrated that this consideration played a 
major role in contributing to AZ’s global knowledge base. Apart from innovation activities, AZ 
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further expanded its production scale in 2006 with an additional US$35 million investment in its 
Wuxi site, which also obtained China and European Union Good Manufacturing Practice 
certification for exporting to the European Union and other countries adopting the same standards. 
This development was the foundation of AZ China’s important global role later. 
 In summary, by 2009, AZ employed more than 2,900 staff locally in China, had a network 
of more than 20 marketing and sales offices, a global manufacturing site in Wuxi, clinical research 
facilities and multiple collaborations and partnerships with local academic and medical 
institutions. Their major projects during this period reflected an emphasis not only on market 
expansion through HBKE-S, but also on LBKE-S to deepen its involvement in the Chinese market 
in the long run. Apart from improved institutional conditions (e.g. the availability of R&D 
resources and government support policies), the company’s increased local knowledge and 
experience is likely to have been a reason for the changing emphasis.  
Third period of expansion in China (2009–2017): The South-North wave and HBKA-S 
This period witnessed the most significant development in terms of localized and global 
innovation. It also saw the strengthening of the Chinese government’s policy and funding support 
for more advanced innovation activities, including National S&T Major Projects for priority 
industries, the National S&T Innovation Base Program for establishing new research laboratories 
and bases, and the establishment of the National Natural Science Foundation of China for 
improving the funding environment for basic research (China Ministry of Science and Technology, 
n.d.). During this period, AZ China deepened its involvement in LBKE-S but also initiated 
activities associated with HBKA-S. In seeking LBKE-S, AZ opened its new Chinese site in 
Shanghai Zhangjiang Hi-Tech Park (which was commonly known as ‘China’s Medicine Valley’) 
in September 2009, which included AZ’s new Chinese corporate headquarters for China and the 
Asia Pacific, its marketing operations, its Innovation China Centre, and academic training and 
regional functions. It became one of only three corporate headquarters of AZ PLC alongside the 
USA and the UK (AstraZeneca Annual Report, 2009; China Pharmaceutical Industry Investment 
Promotion Report, 2014). By the end of this financial year, AZ’s accumulated sales in China were 
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more than US$800 million. AZ was confident that with a population of 1.3 billion in China, a 
burgeoning middle class and an increasing prevalence of Western-style diseases, the Chinese 
market offered the largest opportunity for growth, and was convinced that new product offerings 
were the way to further strengthen its position (Thomson Reuters, 2010).  
Hence, in order to broaden and improve its product offerings, AZ continued its aggressive 
innovation localization in a number of ways. First, AZ strengthened its efforts in internal 
innovation capability building in China. For instance, by 2011, its Innovation China Centre had 
already built strong capabilities in translation sciences for oncology research for the Chinese 
market. As a result, the centre embraced the new mission to deliver candidate drugs and ultimate 
Proof of Concepts and valuable drugs to address the significant unmet medical needs of patients in 
China, such as for liver and gastric cancer (McKinsey Quarterly, 2012). 
Second, AZ also brought in external capabilities to complement its core internal expertise 
already available at its China centre. One example was an acquisition agreement with a privately-
owned generics manufacturing company (BeiKang Pharmaceutical Company Ltd) in 2011, which 
gave AZ access to a portfolio of injectable drugs used to treat infections suffered by Chinese and 
Asian patients (China Drug Review, 2012). This move reinforced the company’s commitment to 
bringing original and high quality branded generic drugs to the Asia-region market to increase their 
accessibility and affordability for patients who were previously underserved. 
More importantly, AZ continued to forge extensive and advanced research collaborations 
with local partners in China for medical breakthroughs. This move was made to not only address 
the medical needs of the Southern market, but also to seek opportunities to meet global market 
needs. A list of some of the major collaborations during this period is provided in Table 5. During 
this period, AZ China entered into several research collaborations for developing drugs for the 
global market. This move signalled AZ China’s first move towards becoming a global contributor 
of innovation – the start of the South-North wave. For instance, in 2011, AZ and Chi-Med China 
joined together to co-develop and commercialize a novel cancer therapy called Volitinib (which 
later turned out to be successful) and, in 2014, it signed an agreement with Tianjin Medical 
University for cardiovascular research collaboration to explore novel targets against cardiac 
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fibrosis. Meanwhile, products such as Tagrisso and Brilinta were the outcomes of R&D 
collaboration between AZ China and AZ’s R&D sites worldwide (Greig, 2016; Zhou et al., 2017). 
By the end of 2014, AZ had recorded over 1,500 patents with the State Intellectual Property Office 
in China (SIPO, 2015). Thus, the increased product offerings and strengthened research 
collaborations with local partners in the third period show a greater emphasis on local innovation 
for the local and global markets. This was built on more favourable local conditions and AZ’s 
greater local knowledge and experience. 
Table 5. List of collaborations  
Year 
 
Means of Innovation Activity 
 
Purpose of Innovation Activity Target 
Market 
2010 Partnership agreement with Peking 
University 
Discovery and development of new 
treatments for diabetes, obesity and 
atherosclerosis 
Chinese 
and global 
patients 
 
2010 Partnership agreement with No. 1 
Affiliated Hospital of Guangzhou 
Medical College 
Basic research on chronic obstructive 
pulmonary disease 
Chinese 
patients 
 
 
2010 Research collaboration with BioDuro 
Clinical Research 
Discovery research in respiratory and 
inflammatory diseases 
Chinese 
and global 
patients 
 
2011 Research collaboration with Chi-Med 
China 
Development and commercialization 
of a novel cancer therapy called 
Volitinib 
Global 
patients 
 
 
2012 Partnership agreement with 
WuXiAppTec, and support from 
AZ’s US biotech subsidiary 
Medimmune  
Development and commercialization 
of a novel biologic for autoimmune 
and inflammatory diseases 
Chinese 
patients 
 
 
 
2012 Research collaboration with 
Ironwood Pharmaceuticals, 
Inc. 
Development and commercialization 
of linaclotide for irritable bowel 
syndrome with constipation and 
chronic idiopathic constipation 
Chinese 
and global 
patients 
 
 
2014 Research collaboration with 
Shenzhen University Health Science 
Centre 
Pre-clinical research on chronic 
kidney disease 
Chinese 
patients 
 
 
2014 
 
 
2016 
 
 
 
 
Partnership agreement with Tianjin 
Medical University 
 
Partnership agreement with 
WuXiAppTec 
 
 
 
Cardiovascular research to explore 
novel targets against cardia fibrosis  
 
Advanced research for addressing 
respiratory, inflammation and 
autoimmunity, cardiovascular and 
metabolic diseases, and oncology 
 
Global 
patients 
 
Chinese 
and global  
Patients 
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2017 Strategic joint venture (namely Dizal 
Pharmaceuticals) with Future 
Industry Investment Fund China 
Discover, develop and commercialise 
new medicines 
Chinese 
and Global 
patients 
(Source: www.astrazeneca.com/partnering; China Food and Drug Administration; ThomsonReuters) 
From 2016 onwards and in alignment with the introduction of the Healthy China 2030 
initiative (Biopharmadive News, 2018; Tan et al., 2017), AZ undertook several major advanced 
R&D projects which further reflect the importance of China as an important R&D location for 
meeting the needs of both Chinese and global markets. An example worth noting is the strategic 
alliance AZ formed with WuXi AppTec to produce next-generation medicines by undertaking 
advanced research in the area of new small molecule development, which is part of AZ’s global 
R&D network and core to AZ PLC (Washington Business Journal, 2017). This project aimed to 
address the needs of both Chinese and global patients in the main therapy areas of respiratory, 
inflammation and autoimmunity, cardiovascular and metabolic diseases, as well as oncology. This 
partnership required not only financial investment but also recruitment of at least 50 world-class 
scientists to establish a new R&D hub for small molecule research, making China an important 
location alongside AZ’s UK and Sweden R&D centers (AstraZeneca Annual Report, 2016; 
Financial Times, 2016). By 2017, AZ showed a further 7% growth in sales compared to its 
competitors. In 2017 alone, a number of key developments took place, illustrating the increasingly 
important role of AZ China in the global innovation network. For one, the formation of the 
strategic joint venture of Dizal pharmaceuticals with the Future Industry Investment Fund for 
discovery, development, and commercialization of new medicines for unmet global needs 
cemented the expansion of AZ’s R&D in China. This occurred at a time when AZ’s competitors 
were consolidating their operations by closing major R&D facilities (Fiercebiotech News, 2017). 
In late 2017, the research collaboration with Chi-Med led to a global clinical trial for a rare type of 
kidney disease found worldwide (Chi-Med, 2017; Reuters, 2017). Further, the research 
collaboration with Ironwood Pharmaceuticals, Inc. led to an application to the China Food and 
Drug Administration for the development and marketing of linaclotide (Ironwood, 2018), whereas 
the launch of PT010 for COPD and asthma in China and Japan, ahead of their launch in Europe 
and the USA, signalled the rise of China as a strategic location for knowledge creation 
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(Fiercebiotech News, 2017). Most recently, AZ China responded to Chinese institutional reforms 
in the implementation of the ‘digital China strategy’ by initiating collaborations with Wuxi 
National Hi-Tech District and Jiangsu Mobile as well as with China's technology giants, Tencent 
and Alibaba, to provide ‘smart’ healthcare services driven by artificial intelligence and internet-
enabled technologies (Biopharmadive News, 2018; China Daily News, 2018). 
To summarize the three periods analyzed above, Figure 2 illustrates the major changes in 
AZ’s activities in China between 1993 and 2017. In the context of the proposed waves framework 
(Figure 1), we can identify a case-informed evolutionary pattern. Period one can be characterized 
as the North-South wave for the main purpose of market expansion through HBKE-S, reflecting a 
market-seeking motivation. Period two maintained activities of period one while the focus shifted 
to LBKE-S for meeting distinct local and regional market demands, a reflection of the South-South 
wave where knowledge-seeking activities emerge. Finally, period three maintained activities of the 
first two periods while the focus shifted to HBKA-S for meeting global market demand, a 
reflection of the South-North wave. This became a new variant of knowledge-seeking activities 
aimed at developing and producing new products that were expected to supply the global market. 
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Discussion and conclusion 
 
 
AZ’s R&D Evolution in China 
 
Having presented AZ’s innovation activities in China in three consecutive periods over the 
course of more than two decades, we now reflect on each of the three major waves and the overall 
evolution pattern identified in the case study in light of the proposed framework (Figure 1). We 
highlight our key findings in order to develop new insights into the latest development in R&D 
internationalization towards the South. 
Period one (North-South wave and HBKE-S): During the period of 1993 to 2001, China 
remained a location with two distinct characteristics: an emerging market and an abundance of 
low-skilled labour for low-cost production. Furthermore, we highlighted that although China 
became a location for AZ’s R&D activities, these activities were mainly an ‘operational necessity’ 
(Bartlett and Beamish, 2013; Cantwell, 1992; Pearce and Papanastassiou, 1997) and were restricted 
to product and production-related HBKE-S (Kuemmerle, 1999; Bas and Sierra, 2002; von Zedtwitz 
and Gassmann, 2002; Liu and Chen, 2012). It could be argued that findings from this period also 
reflected the wider environmental conditions in China at the time, which could be characterized as 
having significant weaknesses in the institutional conditions for more advanced R&D activities. 
During this period, the country showed little or no signs of the availability of R&D resources or 
supportive government policies.  
Specifically, our case study findings show that most of the activities of AZ China during 
this period were related to assimilating knowledge transferred from the headquarters and 
modifying existing products to meet the local market conditions in China through extensive 
localized clinical trials. These activities of product adaptation and localization were achieved in the 
form of in-house R&D support and collaboration with local Chinese hospitals to ensure safety and 
suitability of drugs to Chinese patients. Similarly, Zhang and Pearce (2010) and Zhang et al. 
(2018) note that market-seeking subsidiaries in China incorporated a strong element of product 
adaptation in local operations. Thus, in order to meet the idiosyncratic demand conditions in China, 
local sourcing of technology became an essential precondition.  Furthermore, our empirical 
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findings also concord with the works of Schmiele and Mangelsdorf (2009) and Liu and Chen 
(2012) in that MNEs can gain economic returns from utilizing their existing proprietary knowledge 
(generated in AZ’s global R&D centres) in overseas locations (in this case, China). 
Hence, we argue that AZ’s internal motive for entering China during this period was 
market expansion, which was strongly facilitated by two co-existing factors at the time: ownership 
advantages and local conditions (Dunning, 1998; Bartlett and Beamish, 2013). Specifically, the 
long-established R&D base in the North provided AZ the knowledge-based competitive advantages 
it needed to target markets of the South in pursuit of market-seeking investments (Cantwell et al., 
2010; Kuemmerle, 1999). In contrast, indigenous firms in China were severely lagging behind in 
terms of innovation. At the same time, China’s economic liberalization started to show positive 
signs, such as growing consumption (Fan and Wang, 2001). This development in the local 
institutional conditions provided AZ with the opportunity to potentially take over the market by 
way of offering drugs that were produced with knowledge from the North and labour from the 
South.   
 Period two (South-South wave and LBKE-S): Whilst AZ continued to further invest in 
market expansion activities in China during this period (2002-2008), benefiting from fast economic 
growth, the company also showed first signs of local-based R&D activities. That is, on top of its 
existing R&D activities relating to local adaptation in period one, the company initiated new 
projects into advanced drug testing and discovery specifically targeted at local diseases in China. 
This is in line with the work of Zhang and Pearce (2012) who find that MNEs in China are not 
solely receivers of headquarters knowledge, but also generators of new knowledge by working 
closely with local universities, firms, and research institutions in their effort to augment their 
market-seeking activities. Following our proposed framework, this development in the case of AZ 
China signals an important evolutionary step along the continuum of AZ China’s pattern of R&D 
internationalization, where the North-South wave (identified in period one) shifts towards the 
South-South wave through LBKE-S. China, as an exemplar of the South, is no longer viewed only 
as a source of low-cost labour, but also a new source of R&D knowledge (Awate et al., 2015; Jha 
et al, 2015; von Zedtwitz et al., 2015). Knowledge-seeking in the South emerges as a priority for 
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the company in this wave. Subsidiaries in the South have started to play the role of generating new 
knowledge, as also evidenced by Zhang et al. (2018: 10) who indicate that “the main sourcing of 
new technologies is thus expected to be well diversified and come primarily from the [emerging-
economy] subsidiary… as well as from subsidiary collaborations with local firms and research 
institutions”. 
 The case of AZ China thus shows that this period could be characterized as the seeking and 
development of knowledge useful in providing new products to the local market. There are two 
fast-changing forces that contribute to this trend: improvements in both market and institutional 
conditions in China. In terms of market conditions, the growing market demand and limited 
availability of effective products called for localized innovation. In terms of institutional 
conditions, increased availability of R&D resources and supportive government policies provided 
better conditions for undertaking localized innovation. The imperative to adapt to specific 
conditions in the Chinese market also concords with the propositions by Zhang and Pearce (2010) 
that suggest a variant of market-seeking investments whose aim was to allow for the adaptation of 
these technologies “to local tastes or needs, to cultural mores and to indigenous resources and 
capabilities” (Dunning and Lundan, 2008:70). Though such adaptation also occurred in period one, 
the way it was implemented at the subsidiary level in period two, and the different sources of 
technology that were invoked to secure it, may establish a more important role. For instance, our 
findings show that AZ was able to benefit from increased availability of high quality local medical 
talent and set up many R&D collaborations with local universities and firms, facilitated by 
government initiatives. Our findings further show that AZ’s localized innovation in China enabled 
the company to better understand local diseases, conduct trials, and produce more effective drugs 
for Chinese patients. Consequently, the company was able to retain a secure market share and 
sustainable economic returns.  
 Hence, we argue that although AZ’s internal motive for continuing to establish itself in 
China during this period was local responsiveness, this was achieved through knowledge-
augmenting rather knowledge-exploiting R&D (Bartlett and Beamish, 2013; Dunning and Narula, 
2005). Specifically, the long-established R&D base in the North was no longer the sole source of 
32 
competitive advantage (Kuemmerle, 1997). Instead, working with local counterparts during period 
one enabled AZ to learn more about both the market and the institutional environment (Zhang and 
Pearce, 2012). Local knowledge access thus became an important channel for enhanced ownership 
advantage.  While in the first period there is a clear dichotomy between MNE ownership 
advantages (in the form of established home-based knowledge inputs transferred to China) and 
location advantages (in the form of distinctive demand conditions and the supply of cheap labour 
and technical skills), the enhanced ownership advantage was the outcome of the interactive 
collaboration between the company and local knowledge sources, aiming at knowledge-seeking 
investments (Bartlett and Beamish, 2013). Demand for better products increased significantly in 
this wave whilst upgrading of knowledge capabilities and improvement of China’s legal 
framework also progressed well. Thus, AZ’s shifting internal motive was facilitated and supported 
by the dynamic and interdependent evolution in ownership and location advantages contributing 
towards “the dynamic competitiveness and locational strategy of firms, and particularly the path 
dependency of the upgrading of their core competencies” (Dunning, 2000:167). 
Period three (South-North wave and HBKA-S): The analysis of period three (2009-2017) 
data shows the most striking development of AZ China to date. The company intensified its South-
South and LBKE-S commitment by innovating for not only China, but also the wider Asian region, 
both through utilising its existing internal R&D capabilities as well as by collaborating with and 
acquiring local companies (e.g. Beikang Pharmaceutical Company Ltd). More significantly, during 
this period, the company showed the first signs of undertaking world-leading R&D for the purpose 
of addressing knowledge gaps in drug discovery for some of the world’s most complex and 
challenging diseases (via its Innovation China Centre). This finding is in line with existing 
literature, which suggests that MNEs establish R&D units in locations where they can access host 
countries’ knowledge for their headquarters (Asakawa and Som, 2008). The main objective of 
these units is to engage in knowledge sourcing and benefit from potential knowledge spillovers 
(Almeida and Kogut, 1999; Feinberg and Gupta, 2004). At this point, the South-North wave and 
HBKA-S in support of the development of complementary and novel knowledge for the global 
market became evident. This development supports the work of Govindarajan and Ramamurti 
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(2011), Govindarajan and Trimble (2012) and Jha et al. (2015) in that R&D units under the South-
North wave display the development of long-term innovative capabilities by taking advantage of 
novel or complementary knowledge in foreign locations. In the case of AZ China, this 
development shows that MNE subsidiaries located in non-conventional locations can gradually 
develop strong innovation capabilities and evolve towards being a more active and differentiated 
player in MNEs’ global innovation networks (Mudambi and Santangelo, 2016). We argue that the 
likely cause of this evolution - as reflected in the AZ China case - is further accumulation of the 
firm’s knowledge on how to best maximize the opportunities offered by improved institutional 
conditions, such as local R&D firms, R&D talents and preferential policies. For example, our 
findings of AZ China show that the development of its distinct knowledge base is contingent upon 
the availability of local R&D resources. The company was able to form long-term partnerships 
with local universities (e.g. Tianjing Medical University) and research institutions (Chi-Med 
China), and strategic joint ventures with government funding bodies (Dizal Pharmaceuticals), 
filling knowledge gaps in the existing global pharmaceutical market. This concords with Liu and 
Chen (2012) in that a MNE host-country R&D mandate in the South is likely to be influenced by 
the changing local conditions, changes that in the AZ case had much to do with increased efforts of 
national and local governments to establish pro-innovation support (Archibugi and Iammarino, 
2002; Lundvall, 1992; 2007). This is evidenced by their investment in higher education and 
training of R&D personnel (e.g. AZ was able to utilize a skilled scientific personnel available in 
various hospitals and research institutions), the development of science clusters (e.g. AZ was able 
to benefit from locating in China’s Medicine Valley of Shanghai Zhangjiang Hi-Tech Park), and 
specific policy support (e.g. AZ was able to deepen its involvement in the development of China’s 
national healthcare system with the strong support and facilitation from the government). Another 
recent investment AZ China made was in the smart healthcare services by collaborating with local 
technological firms. With respect to AZ’s R&D evolution in China during the third period, it is 
thus fair to argue that the North-and-South location hierarchy for MNE R&D activities is 
flattening. The South is seen to become an important part of MNEs’ global innovation network for 
knowledge augmentation (Chen, 2004; Liu and Chen, 2012).  
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Hence, we argue that AZ’s internal motive for deepening its involvement in China during 
this period was worldwide learning (Bartlett and Beamish, 2013; Zhang et al., 2018). This strategic 
shift from market expansion (as found in period one) and local responsiveness (as found in period 
two) can be attributed to further changes in ownership advantages and local conditions when 
compared to the two earlier periods. Through the launch of a series of national S&T programmes, a 
supportive and attractive National Innovation System (NIS) was promoted. Campbell (2013:4) 
notes that “the private sector (or semi-private sector) has now taken the lead in innovation from 
SOEs, and relies on foreign funding along with government support for technology projects. 
Government-supported research institutions are now spread throughout the country, but 
innovation leadership in key centers, especially Beijing, Shanghai, and Guangzhou, has passed to 
private firms”. It was clear that in such a supportive environment AZ was able to gain local 
knowledge at a greater scale and scope than before, and combine local and global knowledge for 
enhanced worldwide ownership advantages. It provided AZ the knowledge-based competitive 
advantages it needed to target not only the Chinese, but also the global market.  
In summary, the discussion of the three consecutive waves of innovation activities in the 
case of AZ China clearly suggests a dynamic and path-dependent pattern (from North-South to 
South-South, and to South-North) that concords with our proposed framework (Figure 1). The 
contextual details of each period reveal evidence that AZ’s initial intention of setting up operations 
in the South (in this case China) was not concerned with strategic knowledge sourcing. It was only 
through both market and institutional transformation and organizational learning that innovation 
activities started to be considered seriously (Campbell, 2013). In this very case, our findings imply 
a possible developmental pattern of co-evolution that has taken place between AZ China and 
China’s various institutions. Drawing on the co-evolutionary perspective (Rodrigues and Child, 
2008; Cantwell et al., 2010; Child et al., 2012), we showed that under conditions of limited 
organizational knowledge and weak institutions, the activities of AZ China started with the 
necessary knowledge transfer from headquarters for local production in the early period. This 
process also ‘naturally’ contributed to the innovation capability of local counterparts who were 
involved in AZ’s operations in China at the time. As market and institutional conditions improved 
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(particularly with much stronger involvement and support from the Chinese government) during 
the second period, innovation activities were upgraded to encompass localized product 
development and customization for the Chinese market. Meanwhile, this deepening relationship 
between China and AZ resulted in the Chinese environment becoming increasingly supportive to 
AZ in the way of new opportunities. This in turn led AZ to invest more capital in China in order to 
develop R&D capabilities, creating a two-way development pattern for both the Chinese 
pharmaceutical industry and AZ China. During the most recent period, apart from continuous 
improvement in market and institutional conditions, AZ’s deepened involvement in, and 
knowledge of, China enabled the company to undertake novel and complementary R&D activities 
to meet global market needs. At the same time, AZ China contributed to the Chinese 
pharmaceutical industry’s innovation capability development with the support and opportunities 
offered by the government. 
The empirical evidence of the three periods (Figure 2) illustrates that each period is 
contingent upon the preceding period and AZ’s relationship with China. The explanation for this 
gradual development is likely to be twofold. First, at the firm level, factors such as organizational 
experience and knowledge of the host-country environment are likely reasons for AZ’s growing 
confidence and R&D commitment in China. At the locational level, factors such as changes to 
market and institutional conditions of the host country are another likely contributor to the 
evolution of AZ’s R&D activities in China.  
In other words, drawing on the co-evolutionary perspective (Rodrigues and Child, 2008; 
Cantwell et al., 2010; Child et al., 2012), the AZ China case demonstrates the importance of the 
linkage between local conditions (external factors) and firm knowledge and motives (internal 
factors) as potentially co-existing determinants of R&D-related FDI in the South. The local market 
potential and production benefits in period one attracted AZ to set up sales and manufacturing 
operations in China, benefiting from HBKE. As AZ became more embedded in the local market 
with improved market knowledge and an increasingly innovative institutional environment 
(particularly with the introduction of national S&T programmes), they were able to utilise some of 
their established local networks (such as partnerships with local hospitals and universities) to carry 
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out higher-value-adding R&D activities. The strategic objective for AZ China thus shifted towards 
LBKE-S during period two. Further deepening of AZ’s relationship with local counterparts (local 
firms, research institutions, hospitals, universities, and patients) and continuously improving 
institutional conditions (government support such as the innovation programmes introduced in 
period two and three) provided AZ China the opportunity to start seeking HBKA-S during period 
three.  Each of the three periods was successful in achieving AZ’s objectives in China and success 
in each period paved the way for the next period as both firm knowledge and the local environment 
continuously improved. Thus, we argue that it is the necessary complementarity between internal 
firm knowledge and the external local environment that has influenced AZ’s objectives and 
performance in China throughout the three periods. The AZ case thus perfectly illustrates the co-
evolutionary developmental pattern introduced by prior research (Rodrigues and Child, 2008; 
Cantwell et al., 2010; Child et al., 2012).  
Contributions to R&D internationalization theory and literature 
Our longitudinal case study of AZ’s historical development over the past two decades, 
with specific reference to the context of China, has offered a rich, contextualized example of a 
possible emerging pattern in MNE global innovation network arrangements. It can be argued that 
R&D internationalization by MNEs of the North to economies in the South is too idiosyncratic to 
be explained by established theories. Most of current understanding is predominantly rooted in the 
context of advanced economies and far fewer studies have explored the contextual details of R&D 
evolution from the perspective of the South. Against this background, our study makes a number of 
relevant contributions. 
First, we contribute to the current literature on MNE global innovation networks by 
constructing a framework that integrates four distinct waves and corresponding R&D objectives to 
create a more complete picture of the internationalization of R&D (Table 1). Prior developments in 
an advanced-economy context did not offer the opportunity or need for such definitions. However, 
the recent shift towards knowledge sourcing from new locations in the South makes such a 
systematic classification important to inform future research. Moreover, our case study findings are 
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found to concord with the four major waves and the corresponding R&D objectives. Furthermore, 
whereas in general, North-centric waves (i.e. North-North and North-South) are established 
phenomena, research addressing South-centric waves (South-South and South-North) is only 
recently emerging (e.g. Awate et al., 2015; Jha et al., 2015; Jha et al., 2018; Liu and Chen, 2012) 
and still sparse. Hence, our historical longitudinal case study of AZ in China presents new evidence 
to underpin further discussions on South-centric waves. 
Second, we contribute to current theories of MNE R&D internationalization by 
constructing an overarching conceptual framework (Figure 1) depicting an evolving pattern of 
MNE R&D activities shifting from the North to the South. The concordance between the waves 
framework and our case study findings (summarized in Figure 2) suggests that the R&D 
internationalization pattern is composed of three consecutive (and mutually inclusive) shifts in 
MNE objectives and operations, from HBKE-S (North-South wave) to LBKE-S (South-South 
wave), and to HBKA-S (South-North wave). The conceptual framework extends our current 
thinking in understanding the overall development of the MNE global innovation network 
arrangement by incorporating the latest trends of R&D in the South (Govindarajan and Ramamurti, 
2011; Dhanaraj, 2016). Our study highlights a multi-layered and ever more globalized innovation 
network arrangement in MNEs in search of sustainable competitive advantages. Additionally, it 
also reveals the possible role of MNE organizational experience and knowledge in capturing local 
opportunities offered by the fast-changing market and institutional conditions in the Southern 
economies.  
Our third contribution lies in the context of our study, whereby we focused on China by 
applying a historical lens to exploring this location for MNE R&D. Whilst China is known to 
represent unique opportunities for MNEs, to our knowledge no studies have traced the evolution 
process of R&D by an MNE in the country as closely as we did. Our article is one of the few to 
apply a longitudinal case study approach to reveal contextual details of R&D evolution in the 
South. In line with Meyer et al.’s (2011) and Liu and Chen’s (2012) views on locational 
differences and the exemplar offered by Wang et al. (2012), we offer insights into the idiosyncratic 
transitions in China from 1993 to 2017, reflecting its importance and distinctiveness as a research 
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context. Hence, our study highlights the need to appreciate contextual differences among the 
Southern economies when studying R&D internationalization.  
Finally, our article contributes to the recent methodological discussions on qualitative 
research (e.g. Doz, 2011; Welch et al., 2011). In particular, we illustrate the suitability of a 
historical longitudinal approach and a single case study design in exemplifying ‘context’ in 
qualitative research. The case of AZ China illustrates one way of conducting contextually rich 
research when the target phenomenon is new or difficult to study (e.g. because of company 
secrecy). The richness of contextual details revealed in this article offers useful empirical insights, 
and we therefore call for more research to adopt a similar approach to investigating new 
developments in international business. This is in concert with Verbeke and Kano’s (2015:415) 
suggestion that: “A business history lens can illuminate the behaviour of developed-economy 
multinationals”. 
Managerial implications 
Our article also has a number of managerial implications. For one, the success of AZ China 
highlights the potential importance of changing institutional conditions in the case of Southern 
economies, as well as the possible role of time and experiential knowledge in understanding and 
deepening R&D-related involvement in the host country. Thus, an important lesson to be learned 
by other MNEs wishing to tap into the knowledge pool of the Southern economies (such as China) 
is not to rush into making major R&D commitments at the outset, but instead, to proceed through a 
more gradual process of learning and trial and error. Whilst many MNEs might have some prior 
operating experience in the South, the national innovation environment is likely to be constantly 
changing and therefore should be considered as a completely new territory, requiring effective and 
accumulated learning. A more incremental approach allows for sufficient time to gain a better 
understanding of the availability of R&D resources, government support policies, and ways to 
establish and maintain effective partnerships with local research counterparts. 
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Limitations and recommendations for further research 
 Despite its important contributions, our study has several limitations that suggest avenues 
for future research. First, there are some common concerns associated with our case study design. 
Despite following a methodological approach found in other studies, the use of a single 
longitudinal case has the limitation that it reflects the development of the chosen case per se and 
therefore should always be very carefully considered in relation to others (Child et al., 2012). It is 
thus likely that another case would reveal a somewhat different picture to the narrative we provided 
in the present article. However, our initial objective was not to provide generalizable outcomes, but 
rather to offer a contextually rich analysis of a particular case in light of the recent developments, 
and based on this, to construct a conceptual framework that can serve as a springboard for future 
research to investigate this increasingly important topic. To extend our understanding of innovation 
in the South, it would be of great value if future research could explore the actual mechanisms of 
the evolution process, as well as the key success factors for the internationalization of R&D 
towards the South. It would also be insightful to investigate the implications of the South-North 
wave on MNEs, institutions, and countries, as this wave of development makes the global 
innovation scene much more complex. Next, it would be interesting to see whether or not AZ 
China’s evolutionary pattern has been followed by other MNEs in either China or other Southern 
economies. Although we do not see AZ’s innovation activities in China as an oddity or outlier, as 
figures from UNCTAD (2012; 2016) and a study by D’Agostino (2015) clearly show a strong trend 
of innovation FDI inflows to the South, whether other MNEs have adopted a similar approach in 
their engagement with Southern economies is an interesting question to pursue. Confirmatory 
studies (based on larger samples) or comparative studies (across industries or countries) informed 
by our research findings would be a useful empirical extension of the present study. We hope that 
the clear delineation of the R&D internationalization waves in our study, using the North and 
South paradigm, will motivate further empirical research to generate new insights into the global 
innovation network arrangement of MNEs. 
In conclusion, using a detailed historical case study, we presented a contextually rich story 
of the evolution of an MNE’s innovation activities in a Southern economy and evidenced the fast-
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growing importance of Southern economies as a new destination for knowledge sourcing. We 
revealed subsequent waves of North-South, South-South, and South-North in the case of AZ China 
and identified the latest evolutionary pattern of MNE internationalization of R&D, from North-
South (HBKE-S) to South-South (LBKE-S), and to South-North (HBKA-S). We argue that this 
development has critical strategic implications for the configuration of MNE global innovation 
networks, as they leverage the availability of lower-cost R&D personnel in the South for local, 
regional, and global competitiveness.  
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